Skip to Main Content
Table 1—

Characteristics of enrolled population and rate of study completion

Treatment sequence
CSII to MDIMDI to CSIIAll subjects
n 50 50 100 
Age (years) 41.7 ± 11.1 44.2 ± 11.0 43.0 ± 11.1 
Sex (%)    
    Male 19 (38) 18 (36) 37 (37) 
    Female 31 (62) 32 (64) 63 (63) 
Race (%)    
    Caucasian 48 (96) 48 (96) 96 (96) 
    Hispanic 2 (4) 1 (2) 3 (3) 
    Asian 0 (0) 1 (2) 1 (1) 
BMI (kg/m227.1 ± 4.1 26.7 ± 4.0 26.9 ± 4.0 
HbA1c at screening (%) 7.5 ± 0.8 7.4 ± 0.8 7.5 ± 0.8 
Duration of diabetes (years) 19.7 ± 11.3 23.9 ± 12.3 21.8 ± 11.9 
Daily insulin dose (IU/kg) 0.54 ± 0.23 (n = 45) 0.54 ± 0.21 (n = 50) 0.54 ± 0.22 (n = 95) 
    Basal 0.27 ± 0.10 0.29 ± 0.14 0.28 ± 0.12 
    Bolus 0.29 ± 0.18 0.25 ± 0.11 0.27 ± 0.15 
Daily basal pump rates (%)    
    One basal rate 12 (24) 6 (12) 18 (18) 
    Two basal rates 6 (12) 7 (14) 13 (13) 
    Three basal rates 14 (28) 14 (28) 28 (28) 
    Four basal rates 18 (36) 23 (46) 41 (41) 
Subjects completing study (%) 45 (90) 46 (92) 91 (91) 
Withdrawals during treatment (%) 5 (10) 4 (8) 9 (9) 
Adverse events (n
Noncompliance (%) 2 (4) 3 (6) 5 (5) 
Ineffective therapy (%) 1 (2) 1 (2) 2 (2) 
Withdrew consent (%) 2 (4) 2 (2) 
Treatment sequence
CSII to MDIMDI to CSIIAll subjects
n 50 50 100 
Age (years) 41.7 ± 11.1 44.2 ± 11.0 43.0 ± 11.1 
Sex (%)    
    Male 19 (38) 18 (36) 37 (37) 
    Female 31 (62) 32 (64) 63 (63) 
Race (%)    
    Caucasian 48 (96) 48 (96) 96 (96) 
    Hispanic 2 (4) 1 (2) 3 (3) 
    Asian 0 (0) 1 (2) 1 (1) 
BMI (kg/m227.1 ± 4.1 26.7 ± 4.0 26.9 ± 4.0 
HbA1c at screening (%) 7.5 ± 0.8 7.4 ± 0.8 7.5 ± 0.8 
Duration of diabetes (years) 19.7 ± 11.3 23.9 ± 12.3 21.8 ± 11.9 
Daily insulin dose (IU/kg) 0.54 ± 0.23 (n = 45) 0.54 ± 0.21 (n = 50) 0.54 ± 0.22 (n = 95) 
    Basal 0.27 ± 0.10 0.29 ± 0.14 0.28 ± 0.12 
    Bolus 0.29 ± 0.18 0.25 ± 0.11 0.27 ± 0.15 
Daily basal pump rates (%)    
    One basal rate 12 (24) 6 (12) 18 (18) 
    Two basal rates 6 (12) 7 (14) 13 (13) 
    Three basal rates 14 (28) 14 (28) 28 (28) 
    Four basal rates 18 (36) 23 (46) 41 (41) 
Subjects completing study (%) 45 (90) 46 (92) 91 (91) 
Withdrawals during treatment (%) 5 (10) 4 (8) 9 (9) 
Adverse events (n
Noncompliance (%) 2 (4) 3 (6) 5 (5) 
Ineffective therapy (%) 1 (2) 1 (2) 2 (2) 
Withdrew consent (%) 2 (4) 2 (2) 

Data are means ± SD or n (%). Treatment sequence refers to the order of insulin administration in the two treatment periods (i.e., CSII to MDI refers to CSII treatment during period 1 and MDI treatment during period 2).

Close Modal

or Create an Account

Close Modal
Close Modal